Cyclodextrins: Efficient biocompatible solubilizing excipients for bromhexine liquid and semi-solid drug delivery systems.
Bromhexine hydrochloride (bromhexine) is a mucolytic agent with very low aqueous solubility. However, with addition of cyclodextrins (CD) to the formulation, this disadvantage may be limited and therapeutic doses of bromhexine in solution can be achieved. The interaction of bromhexine with α-, β-, γ- and sulfobutylether (SBE)-β-CD, respectively, was elucidated by means of phase solubility diagrams and calorimetric analysis. The complexes were further characterized by size, and the effect of the CD concentrations used was evaluated in a viability assay. From phase solubility diagrams with α-, β-, γ- and SBE-β-CD and bromhexine, it was determined that the solubility of bromhexine significantly increased with addition of CDs, showing an A(L) type solubility curve for bromhexine/α- and β-CD, and an A(N) type for bromhexine/γ- and SBE-β-CD. The highest soluble concentrations of bromhexine were achieved with α- and SBE-β-CD, i.e. when using a 100mM α- or SBE-β-CD solution, 4 and 5.5 times more bromhexine was solubilized, respectively, compared to pure aqueous solubilization of bromhexine. The apparent association constants determined from the phase solubility studies showed very low values of 34, 17, 8 and 156 M(-1) for bromhexine/α-, β-, γ- and SBE-β-CD, respectively, as compared to the association constants determined by ITC which exhibited values of 89, 307 and 1680 M(-1) for bromhexine/α-, β- and SBE-β-CD, respectively. The formation of aggregates aided solubilization of bromhexine in the phase solubility studies explaining the difference in the association constants between the two methods. Due to very low signal to noise ratio, no information was extracted for bromhexine/γ-CD solutions from the ITC measurements. The effect on cellular viability of the CDs ranked β->α->SBE-β->γ-CD. In conclusion, the results altogether demonstrated that SBE-β-CD is the most suitable CD for future drug delivery systems from the aspect of high amounts of solubilized bromhexine and high safety of the SBE-β-CD.
Department of Biotechnology, Chemistry and Environmental Engineering, Aalborg University, Sohngaardsholmsvej 57, Aalborg 9000, Denmark.
Mladen
M
Stojanov
Hanne Mørck
HM
Nielsen
Kim L
KL
Larsen
D000818:Animals; D001672:Biocompatible Materials; D001964:Bromhexine / Q000737:chemistry*; D002151:Calorimetry; D002470:Cell Survival / Q000187:drug effects; D002626:Chemistry, Pharmaceutical; D003505:Cyclodextrins / Q000737:chemistry* / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D004337:Drug Carriers; D004339:Drug Compounding; D005079:Excipients / Q000737:chemistry*; D005100:Expectorants / Q000737:chemistry*; D006367:HeLa Cells; D006461:Hemolysis / Q000187:drug effects; D006736:Horses; D006801:Humans; D010316:Particle Size; D012995:Solubility; D013678:Technology, Pharmaceutical / Q000379:methods; D047391:alpha-Cyclodextrins / Q000737:chemistry; D047392:beta-Cyclodextrins / Q000737:chemistry; D047408:gamma-Cyclodextrins / Q000737:chemistry
D001672:Biocompatible Materials; D003505:Cyclodextrins; D004337:Drug Carriers; D005079:Excipients; D005100:Expectorants; D047391:alpha-Cyclodextrins; D047392:beta-Cyclodextrins; D047408:gamma-Cyclodextrins; C093196:SBE4-beta-cyclodextrin; D001964:Bromhexine